[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2026.02.25.8814Pharm Sci Asia 2026; 53(2), 112-121
 

Ivermectin ameliorates cyst progression in polycystic kidney disease rats and renal cell-derived cysts via suppression of chloride secretion

Kanlayanee Tonum1, Nipitpon Srimai2, Sunhapas Soodvilai2*

1 Department of Physiology, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand
2 Research Center of Transporter Protein for Medical Innovation, Department of Physiology, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand


Polycystic kidney disease (PKD) is a genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Ivermectin is an antiparasitic drug that has been reported to function as an agonist of the farnesoid X receptor (FXR). Activation of FXR has previously been shown to attenuate cyst progression. In the present study, we evaluated the pharmacological effects of ivermectin on renal cyst progression in vivo in a rat model of PKD and in vitro in renal cell-derived cysts. Daily subcutaneous administration of ivermectin (0.5 mg/kg body weight) for 12 weeks significantly reduced the kidney weight–to–body weight ratio and improved renal function in PKD rats compared with vehicle-treated controls. In addition, treatment with 2 µM ivermectin significantly inhibited Madin–Darby canine kidney (MDCK) cell-derived cyst formation by 31 ± 5.3% compared to vehicle-treatment. These effects were associated with suppressed cell proliferation and reduced phosphorylation of extracellular signal-regulated kinases (ERK)1/2. In addition, ivermectin significantly attenuated in vitro cyst growth by 13 ± 3.0% compared with control. This inhibitory effect on cyst growth was associated with reduced cystic fibrosis transmembrane conductance regulator (CFTR)– and TMEM16A-mediated chloride secretion by 36 ± 3.1% and 12 ± 2.8%, respectively, compared with control. Collectively, these findings demonstrate that ivermectin inhibits renal cyst progression both in vivo and in vitro, supporting its potential as a pharmacological modulator of cyst growth in PKD.


Keyword:

Ivermectin; Repurposing drug; Chloride secretion; Kidney; Farnesoid X receptor




Download full paper (PDF File size: 877.85 KB.)





Vol.53
No.2
April-June 2026

See other volume

 


Vol.53
No.1
January-March 2026

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University



Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2026
    Faculty of Pharmacy, Mahidol University, THAILAND
 

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.